Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel
- 1 October 2004
- journal article
- review article
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 8 (5) , 321-337
Abstract
Approximately 2% of people worldwide have psoriasis, with as many as 1 million people with psoriasis in Canada alone. 1 , 2 The severity of psoriasis ranges from mild to severe. It can lead to substantial morbidity and psychological stress and have a profound negative impact on patient quality of life. 3 , 4 Although available therapies reduce therapies reduce the extent and severity of the disease and improve quality of life, 3 reports have indicated a patient preference for more aggressive therapy and a dissatisfaction with the effectiveness of current treatment options. 5Keywords
This publication has 68 references indexed in Scilit:
- Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasisJournal of the American Academy of Dermatology, 2004
- Long-term use of intravenous alefacept: safety and off-treatment responses in patients who have received four or more courses of therapyJournal of the American Academy of Dermatology, 2004
- The efficacy and safety of etanercept in the re-treatment of psoriasis after relapseJournal of the American Academy of Dermatology, 2004
- Continuance on etanercept after early incomplete response in patients with psoriasisJournal of the American Academy of Dermatology, 2004
- The quality of life of patients with severe psoriasis treated with infliximabJournal of the American Academy of Dermatology, 2004
- Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: pooled results from randomized phase III trialsJournal of the American Academy of Dermatology, 2004
- AAD consensus statement on psoriasis therapiesJournal of the American Academy of Dermatology, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Cyclosporine as maintenance therapy in patients with severe psoriasisJournal of the American Academy of Dermatology, 1997
- Psoriasis of early and late onset: Characterization of two types of psoriasis vulgarisJournal of the American Academy of Dermatology, 1985